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Assessment of side effects induced by injection
of different adjuvant/antigen combinations in
rabbits and mice
P. P. A. M. leenaars'·2.3, M. A. Koedam', P. W. Wester', V. Baumans4,
E. Claassen3,5 & C. F. M. Hendriksen'
'Nationallnstitute of Public Health and the Environment (RIVM). Bilthoven, 2Division Immunological
and Infectious Diseases, TNO Prevention and Health, Leiden, 3Department of Immunology, Erasmus
University Rotterdam, 4Department of Laboratory Animal Science, Utrecht University and Sinstitute
for Animal Science and Health (ID-DLO), Lelystad, The Netherlands
Summary
We evaluated the side effects induced by injection of Freund's adjuvant (FA)and alternative
adjuvants combined with different antigens. Rabbits and mice were injected subcutaneously,
intramuscularly (rabbits) and intraperitoneally (mice) with different adjuvants (FA,Specol,
RIBI,TiterMax, Montanide ISA50) in combination with several types of antigens (synthetic
peptides, autoantigen, glycolipid, protein, mycoplasma or virusesl. The effects of treatment
on the animals' well-being were assessed by clinical and behavioural changes (POT and
LABORASassays) and gross and histopathological changes. In rabbits, treatment did not
appear to induce acute or prolonged pain and distress. Mice showed behavioural changes
immediately after (predominantly secondary) immunization. Injection of several adjuvant/
antigen mixtures resulted in severe pathological changes, depending on adjuvant, type of
antigen, animal species used and route of injection. Both rabbits and mice showed
pathological changes ranging from marked to severe after injection of FA, and ranging from
minimal to marked after Specol and Montanide injections. Pathological changes after RIBI
injections were severe in rabbits, though slight in mice. After TiterMax injections,
pathological changes were moderate in rabbits, though severe in mice. In conclusion,
injection of FA according to present guidelines resulted mostly in severe pathological
changes, whereas only very few clinical and behavioural signs indicated prolonged severe
pain. Our findings indicate that Montanide ISA50 and Specol induce acceptable antibody
titres, and cause fewer pathological changes than FA. Thus they are effective alternatives
to FA.
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Immunization procedures are frequently
applied in laboratory animals, in many cases
to produce specific polyclonal antibodies to
different kinds of weakly immunogenic
antigens. The immune response is enhanced
Correspondence to: Marlies Leenaars, RlVM, PO Box 1, 3720
BA Bilthoven, The Netherlands. Fax: +31-30-2744408.
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by adding an adjuvant to the antigen.
Freund's complete adjuvant (FCA)is com-
monly used for this purpose, because it
evokes high-level and long-lasting humoral
and cellular immunity to a wide range of
antigens. However, on account of its severe
side effects the use of FCA in laboratory
animals is now discouraged (e.g. Canadian
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Council on Animal Care 1991, Veterinary
Public Health Inspectorate 19931.Alternative
adjuvants have been recommended to reduce
pain in immunized animals (reviewed in
Claassen & Boersma 1992, Vogel & Powell
1995, Cox & Coulter 1997). An effective
alternative to FCA would be an adjuvant that
induces minimal side effects and acceptable
antibody responses. It should also be easy to
prepare, commercially available and inex-
pensive. Most adjuvant evaluation studies
emphasize the immunological properties.
Because the aim of finding an alternative to
FCA is reducing pain and distress in labora-
tory animals, the side effects evoked by
administration ought to be considered as
well.
These side effects may be assessed on
clinical, behavioural, biochemical, and his-
topathological grounds. Morton and Griffiths
(1985) and Wallace et a1. (1990) issued
guidelines on the recognition of pain, distress
and discomfort in experimental animals.
Assessment includes general appearance,
body weight, clinical signs, unprovoked
behaviour, and responses to appropriate
stimuli. Elevated levels of hormones or
metabolites may serve as indicators of pain,
though interpretation may be problematic
(Broom & Johnson 1993). Irwin (1968) devel-
oped the Primary Observation Test (POT) to
assess pain after injection of pharmacological
agents. Jansen van 't Land and Hendriksen
(1995) described a system based on locomotor
activity to evaluate discomfort. A recently
developed behaviour registration system,
LABORAS, (Van de Weerd 1996, Bulthuis et
a1. 1997) automatically records six different
categories of behaviour (immobility, loco-
motion, climbing, grooming, eating, drink-
ing) during prolonged periods of time.
LABORAS seems promising for extensive
behavioural studies. Side effects of adjuvants
can also be assessed on gross and histo-
pathological changes.
Side effects occurring after administration
of FCA are well-documented but studies
evaluating side effects induced by alternative
adjuvants are scarce (Johnston et a1. 1991,
Deeb et a1. 1992). To obtain more informa-
tion on side effects induced by FA and alter-
native adjuvants, we performed comparative
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studies in rabbits and mice. The studied
alternative adjuvants (Specol, RIBI, TiterMax
and Montanide ISA50) are commercially
available and easy to prepare. Antibody
responses and clinical, behavioural, and
pathological changes were compared after
injection of different combinations of
adjuvant and antigen by different routes.
Animals, materials and methods
Animals
New Zealand White rabbits (Oryctolagus
cuniculus) of both sexes were obtained from
the specific-pathogen-free (SPF)breeding
centre of the National Institute of Public
Heath and the Environment (RIVM) in
Bilthoven, The Netherlands. The rabbits
were about 6 months old and weighed
between 3.5 and 4.0 kg initially. They were
individually housed in stainless steel or plas-
tic cages, at environmental temperature 20-
21°C, and under a 12 h day/night light cycle.
The relative humidity ranged between 45 and
60%. They were fed rabbit chow (80g/day,
Hope Farms BY,Woerden The Netherlandsl, ,
and tap water was available ad libitum.
BALB/c/Rivm mice of both sexes were bred
SPF at the RIVM breeding facilities and were
used at 10-14 weeks of age. They were housed
in groups of five mice (one sex) under SPF
conditions in Macrolon type II cages, at
environmental temperature of 20-22°C, rela-
tive humidity 50-70%, and under a 12 h day/
night light cycle. They were fed a commercial
diet (Hope Farms BV,Woerden, The Nether-
lands) and provided with tap water ad libitum.
The behavioural experiment LABORAS was
conducted at Utrecht University. Female
BALB/cAnCrRyCpbRivU mice maintained at
the Central Laboratory Animal Institute
(GDL), Utrecht University, The Netherlands,
were used at 10-12 weeks of age. These mice
were housed individually in Macrolon type II
cages, at environmental temperature 20-22°C,
relative humidity 50-70%, and under a
reversed 12 h day/night light cycle.
Adjuvants
Freund's complete adjuvant (FCA; Difco
Laboratories, Detroit, MI) consists of 85%
Adjuvant induced side effects in rabbits and mice
paraffin oil (mineral oil; Bayol F) and 15%
emulsifier (mannide monooleate) with added
heat-killed Mycobacterium butyricum
(0.5mg/ml). Freund's incomplete adjuvant
(FIA; Difco Laboratories, Detroit, MI) con-
tains the same ingredients as FCA, except fot
mycobacteria. The term FA is used in this
paper to indicate that FCA was used in pri-
mary and FIA in secondary injection. Specol
(ID-DLO, Lelystad, The Netherlands; Bokh-
out et al. 1981, Boersma et al. 1992) is 90%
mineral oil (Marcol 521and 10% emulsifier
(Span 85 and Tween 85). RIBl (Sanbio BV,
Uden, The Netherlands; Rudbach et al. 1995)
consists of metabolizable oil (squalene; 2% in
final volume of adjuvant/antigen I, emulsifier
(Tween 80) and microbial components:
0.5 mg/ml monophosphoryllipid A (MPL),
0.5 mg/ml synthetic trehalose dicoryno-
mycolate (TDMI and (when used in rabbits)
0.5 mg/ml cell wall skeleton (CWS). Titer-
Max (CytRx, Norcross, GA; Hunter et al.
1995) consists of a metabolizable oil (squa-
lene), emulsifier (sorbitan monooleate 80), a
patented block copolymer CRL-8941 and
microparticulate silica coated with CRL-
8941). Montanide lSA50 (Seppic, Paris,
France; Ganne et al. 1994) consists of 85%
mineral oil and 15% emulsifier (mannide
oleate). Mixing FCA, FIA, Specol, Montanide
or TiterMax with aqueous antigen solution
produces water-in-oil emulsions. Mixing
RIBl with aqueous antigen solution produces
an oil-in-water emulsion.
Antigens
Synthetic peptide (SPekl5a, 27 amino acids,
containing a Band T cell epitope) was syn-
thesized as described by Zegers et al. (1993).
Synthetic peptide (SP215, 21 amino acids, a
homologue to the hinge region of the human
19G2 molecule) was synthesized as described
by Boersma et ai. (1989). Myelin basic protein
(MBP; Sigma, St Louis, MOl is an autoantigen
derived from the bovine brain, and consists of
173 amino acids, 18.5 kDa (Van Noort et al.
1993). Galactocerebroside (MBL-TNO, Rijs-
wijk, The Netherlands; Gerritse et al. 1993)
is a glycolipid. Bovine serum albumin (BSA)
was obtained from Sigma, St Louis, MO
(A-9647). Measles virus (Edmonston strain;
389
107 CCIDso/ml; Van Binnendijk et ai. 1994),
rubella virus IHPV-77 strain; 107 CCIDso/ml;
Parkman et al. 1966) and mumps virus
(Enderson strain; 107 CCIDso/ml) were
kindly supplied by Dr N Elzinga (RIVM,
Bilthoven, The Netherlands). HIV peptides
conjugated to tetanus toxoid were prepared
by Dr P. de Vries (RIVM, Bilthoven, The
Netherlands). Mycoplasma pneumoniae
(MAC strain; Su et al. 1990) is a particulate
antigen (0.1-0.8 ~l1n)which was kindly sup-
plied by Dr A Angulo (RIVM, Bilthoven, The
Netherlands). The antigens (amounts per
rabbit in Table 1 and per mouse in Table 2)
were diluted in sterile phosphate-buffered
saline (PBS),except for galactocerebroside
which was diluted in dimethyl sulphoxide
(DMSO).
Adtuvant/antigen preparation
Adjuvant/antigen and adjuvant/PBS mixtures
were prepared according to the manufac-
turer's instructions. Freund's adjuvant emul-
sions were prepared by mixing FA and
aqueous antigen solution [1:1), using two
glass syringes with Luer Lock connector. The
antigen was added to FA via the connector
and mixed for one minute. Specol emulsions
were prepared by adding the aqueous antigen
solution (Specol: antigen = 5: 4) dropwise to
Specol while vortexing. RIBI emulsions were
prepared by warming the RIBIvial to 40-45°C
for 5 min, reconstituting a final volume of
2 ml with the aqueous antigen solution in the
RIBl vial and vortexing for 3 min. TiterMax
was emulsified with aqueous antigen solu-
tion (1:1) similarly to FA, except that the
aqueous antigen solution was added in two
steps. Montanide ISA50 emulsions were
prepared by pouring Montanide lSA50 in a
glass tube, adding the aqueous antigen solu-
tion with a syringe and making 10 up and
down strokes.
Experimental design
Studies were performed in rabbits and mice.
Adjuvant/antigen combinations inducing
obvious problems were not unnecessarily
repeated. The experimental designs for the
studies in rabbits are outlined in Table 1 and
for the studies in mice in Table 2. In rabbits,
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Table 1 Experimental design for immunization studies in rabbits
Exp.la Exp. II Exp. III Exp. IV
FA + + + +
Specol + + + +
RIBI +
TiterMax +
Montanide ISA50 + +
No adjuvant + + +
SPek15a (200) +
Galacto (200) +







S.c., volume in ml 0.5d 0.1 4 x 0.25 4xO.1
I.m., volume in ml 0.5d 0.1
Injection, day 0, 28 0,28 0,35 0, 28, 84
Dissection, day 42 42 49 92





Number of animals injected








aAlso described in Leenaars et a/. (1994)
bSPek15a=synthetic peptide; Galacto =galactocerebroside; M. pneu. =Mycoplasma pneumoniae; BSA=bovine serum
albumin; HIV/peptltt = HIV peptides conjugated to tetanus toxoid
<Amount of antigen described in Antigen section of 'Animals, materials and methods'
dRIBI emulsions: 2 x 0.5 ml; TiterMax emulsions: 0.08 ml (as recommended by the manufacturers)
four experiments were performed, injecting
animals subcutaneously (s.c.) on the flank or
intramuscularly (i.m.) in the posterior thigh.
In order to be able to discriminate between
primary and secondary inoculations, single
adjuvant/antigen injections were given at
separate sites, except in rabbit experiments
III and IV.These experiments were combined
with routine polyclonal antibody production,
involving four injections (s.c.) at one time
point, on account of low concentration of
antigen. In mice, three experiments were
performed. The animals were injected intra-
peritoneally (i.p.) or s.c. in the neck (primary
injection) and s.c. in the groin (secondary
injection). Control rabbits and mice received
antigen only. At selected time points blood
samples were taken to determine antibody
production, except for mice experiment III
(see Table 2), which was a behavioural study
only. Clinical and behavioural abnormalities
occurring during the experiments, and
pathological changes at the end of each
experiment were studied as described below.
Clinical and behavioural parameters
General condition (appearance and clinical
abnormalities) of the rabbits and mice was
observed daily as described by Morton and
Griffiths (1985). Abdomen of i.p. injected
mice and s.c./i.m. injection sites were pal-
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Table 2 Experimental design for immunization studies in mice
Exp.la Exp. la Exp.la Exp. II Exp. III
Adjuvant FA + + + + +




No adjuvant + + + + +
Antigenb MBP (100) +
(fig per injection) M. pneu. (15) +
SP215 (50) + +
No antigen + +
Route S.c., volume in ml 0.2 0.1 0.1 0.1c
I.p., volume in ml 0.2 0.2 0.1 0.2 0.2
Immunization schedule Injection, day 0, 42 0,42 0,42 0, 42 °Dissection, day 49 47 47 47 18
Additional parameters to Body weight + + +
assessside effects POTd + + +
LABORASe +
Number of animals injected per 5 5 5 5 4
route and per adjuvant/antigen
combination
apartly described in Leenaars et al. (1995)
bMBP=myelin basic protein (autoantigen); M. pneu. = Mycoplasma pneumoniae; SP215= synthetic peptide
CTiterMax emulsions: 0.05 ml (as recommended by the manufacturer)
dprimary Observation Test
eLaboratory Animal Behaviour Observation Registration and Analysis System
pated to monitor signs of pain. Injection sites
were examined for swelling the day after
injection and weekly thereafter. Additional
clinical or behavioural parameters were
studied to evaluate side effects (see Tables I
and 2). These parameters are described below.
Body weight, body temperature,
locomotion activity
Rabbits were weighed (experiments I and II)
weekly. Mice (experiment II were weighed
before injection, 3 days after injection and
twice-weekly thereafter. Body temperature of
rabbits (experiment I) was measured twice a
week in a restraining box; after 30 min
acclimatization, the rectal temperature was
recorded four times in 30 min. The mean of
these four temperatures was taken as the
body temperature. Locomotor activity of
rabbits was studied during one week follow-
ing primary and secondary injection, obser-
ving the animals moving freely in the animal
room.
Primary Observation Test
Behavioural changes and physiological state
of the mice were studied (mice experiment II
using the POT. POT is a systematic quanti-
tative procedure described by Irwin (1968)
and modified by Professor Dr B Olivier
(Solvay Duphar, Weesp, The Netherlands).
It involves an initial phase of undisturbed
observation followed by a manipulative
phase during which the animal is subjected
to different stimuli. It was performed before
injection, 3 days thereafter and then weekly.
Per group (n = 51, mice were placed in an
observation chamber. After an adaptation
period of one hour the animals' undisturbed
behaviour, i.e. dispersion in the cage, apathy,
startle-reaction, restlessness, watchfulness
and respiration, was observed. Then the ani-
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mals were individually transferred onto the
viewing arena and arousal response to trans-
fer, spatial locomotion, gait, slip resistance,
righting reflex, exophthalmos and piloerec-
tion, were observed. Then, touch-reflex, pro-
voked-freezing, provoked biting, skin colour,
body tone, pupil size, urination-defecation
and vocalization, were studied throughout
individual handling. After handling, they
were placed in the observation chamber again
to study grooming. Behavioural changes and
physiological state were scored per mouse.
Behaviour registration system LABORAS
A newly developed behaviour registration
system LABORAS(Van de Weerd 1996, Bul-
thuis et a1. 1997)was used to register beha-
vioural patterns of individually-housed mice
(mice, experiment III). LABORASis a fully
automated device capable of deducing these
behavioural categories: locomotion, immo-
bility, climbing, grooming, eating, drinking.
The animal is placed in a Macrolon type II
cage located on a sensing platform. The
mechanical vibrations caused by the animals'
movements are transduced into electrical
signals and recorded. The signals are trans-
lated into the six separate behavioural cate-
gories by computer. On day 0, 15 min before
the start of the dark period (= 15 min before
start of recording period), mice were injected
with FCA or PBS (0.2ml i.p.) and placed in
the cage on the sensing platform. Movements
were recorded during the first 4 h of the dark
period every other day during 16 days. Per day
(i.e. first 4 h of dark period) the relative time
spent on each behavioural category was cal-
culated and analysed. After a square-root
transformation, data were statistically ana-
lysed using a t-test to establish significant
behavioural differences between FCA and
PBSinjected mice. The level of statistical
significance was set at P < 0.05.
Pathology
At the end of each experiment, rabbits were
anaesthetized by intravenous injection of
2.5 ml sodium pentobarbital (60mg/ml)
before bleeding via cardiac puncture. Mice
were anaesthetized before orbital bleeding by
i.m. injection of 0.1 ml of a mixture of keta-
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mine (50mg/ml), xylazine (20mg/ml) and
atropine (1mg/ml) in a 7:3:1 volume ratio.
Necropsy in rabbits and mice included dis-
section and examination of injection sites
and at least abdominal organs. For histo-
pathological evaluation, tissue of injection
sites, a sample of the omentum of all i.p.
injected mice, and tissue of organs showing
macroscopic abnormalities, were fixed in 4%
neutral buffered formaldehyde, embedded in
paraffin, sectioned at 5pm, and stained with
.haematoxylin and eosin. Gross lesions were
documented during necropsy and microscopy
was performed in selected representative
samples. In rabbits and in s.c. injected mice
the primary and secondary injection sites
were scored separately. The scoring was
based on the size and character of the lesions
found. In individual rabbits the severity of
lesions was scored according to Table 3.
Microscopy was used to verify macroscopical
observations (Figs lA-B). In individual mice,
the severity of s.c. lesions was scored (mac-
roscopically and microscopically) accordirig
to Table 4. In order to be able to grade
pathological lesions, taking into account the
supposed discomfort, the categories shown in
Tables 3 and 4 served as a general guideline
for classification. In i.p. injected mice, the
severity of abdominal lesions was mainly
assessed macroscopically, based on the pre-
sence of abdominal effusions, adhesions,
intestinal dilatation, presence of 'plaques'
and omentum retrahens. Microscopical
determination of severity of peritonitis was
used to verify macroscopical observations.
Examples of microscopic severity grade of
lesions in mice are given in Figs lC-F (s.c.)
and Fig lG (i.p.).
Antibody responses
Blood samples were taken to determine
antibody production (except mice experiment
III).As this paper focuses on the side effects
induced by adjuvants, antibody production
results will be summarized. More detailed
information on antibody titres of rabbit
experiment I can be obtained from Leenaars
et a1. (1994)and of mice experiment I and II
from Leenaars et a1.(1995) and Leenaars et a1.
(in press), respectively. Antibody production
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Table 3 Pathological findings at injection sites of rabbits subcutaneously or intramuscularly injected with












• Extensive exudative lesions (generally accompanying granulomatous lesions) with severe
haemorrhage, > 40 cm2
• Abscess-like lesions, diameter > 2 cm
• Ulcus> 1em
• Exudative lesions (generally accompanying granulomatous lesions) with haemorrhage
<20cm2
• Extensive nodular granulomatous lesions 20-100cm2; marked central necrosis in
granulomas; minor signs of acute inflammation
• Ulcus < 1cm
• Nodular granulomatous lesions 1-10cm2, without marked central necrosis and
haemorrhage
• Nodular granulomatous lesions < 1cm2
• Minimal diffuse opacity (flat granulomatous proliferation) and/or minimal or local
hyperaemia or petecchial bleeding 5-25 cm2
• Negative, or minimal local opacity or hyperaemia/petecchiae < 5 cm2
• Granuloma(s) > 1cm 0<, with marked central necrosis
• Granuloma(s) > 2 cm 0<, without marked central necrosis
• Granuloma(s) 0.5-2 cm 0<, without marked central necrosis
• Minimal white or red streaks in muscle, or slight hyperaemia or haemorrhage < 0.5 cm
0<
• Negative
aln some caseslesions were given an in-between score
bWhen different lesions were present, the highest score was used to classify the injection site
<Transversediameter, perpendicular to muscle fibres
Table 4 Pathological findings at injection sites of mice subcutaneously injected with different adjuvant!








• S.c. nodule > 4 mm
• S.c. nodule 2-4 mm
• S.c. nodule 1-2 mm
• S.c. nodule < 1 mm
• S.c. negative; hairless
area <2mm




















> 5 mm or large
amount of white tissue
around thigh muscles




• White mass externally
visible, no swelling; S.c.
slight to moderate
amount of white tissue
• Negative externally; S.c.
minimal amount of
white tissue












• Minimal to slight
diffuse inflammation
aln some casesin-between scores were given
~he macroscopic and microscopic severity grades of a lesion are not necessarily similar
<Exudative nature usually dominates granuloma formation
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Fig lA Rabbit experiment III, s.c. FIAjmeasles virus, 2 weeks after secondary injection, score 8. Microscopical
detail of palpable, extensive haemorrhagic lesions, total surface 300cm2• a: Necrosisof pre-existent tissue, as
shown by pre-existent collagen fibres (arrows), between cellular debris and fibrin. b: Fibroangioblastic
proliferation with hyperaemia and haemorrhage. Considered primarily exudative, no granulomatous
component present (HEx 110)
Fig 1B Rabbit experiment II, S.c.Montanide ISA50jBSA, 2 weeks after secondary injection, score 4.
Microscopical detail of a palpable lesion, grossly described as faint pink tissue with central hyperaemia and
slight haemorrhage, measuring 12cm2 and maximum width O.5cm. Epithelioid granulomas, partly around oil
spaces,and Iympho-plasmacellular infiltrate between subcutaneous collagen fibres. Necrosisabsent (HEx 110)
after adjuvant/antigen injection was corre-
lated to antibody production after FA/antigen
injection. Antibody titre after FA/antigen
injection was set on 100% and antibody titres
after other adjuvant/antigen injections
were expressed relative to the titre after
FA/antigen.
Results
Clinical and behavioural signs
Rabbits
Both after s.c. and i.m. injection, body weight
and body temperature did not significantly
differ between the controllantigen injected)
and experimental (adjuvant/antigen injected)
groups. Clinical abnormalities were observed
in one rabbit, i.m. injected with RIBI/M.
pneumoniae, showing discomfort during
locomotor activity the first 4 days after pri-
mary injection.
Experiments I+II Subcutaneous injection
sites in rabbits showed tissue swelling (see
Table 51. Primary injection sites showed
swelling mainly after FCA injection. At sec-
ondary injection sites, other adjuvants also
caused swelling. FA and RIBI injection most
frequently resulted in swelling. Swellings
increased during 3-4 weeks after primary
injection, and then decreased. Swellings after
secondary immunization increased during
the first week post injection. Intramuscular
injected rabbits showed swellings only at
Specol/BSA secondary injection sites. Palpa-
tion of s.c. and i.m. injection sites, produced
no signs indicating pain.
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Fig 1C Mouse experiment II, S.c. TiterMaxjSP215, 7 weeks after primary injection. Grossly hairless area, S.c.
pale-yellow nodule 5 mm with slight haemorrhage, score 3. Microscopical detail shows acanthosis, severe
fibrosis and diffuse inflammation, with marked cellularity and an occasional small granuloma (g) with central
necrosis, score 3 (HEx 110)
Fig 1D Mouse experiment II, S.c. SpecoljSP215, 7 weeks after primary injection. Grosslywhite nodules < 2 mm
and slight petechial bleeding in interscapular brown fat, score 1. Microscopically slight granuloma formation
around oil spaces,moderate diffuse inflammation (not observable in this detail) and moderate fibrosis, score 1
(HEx110)
Fig 1E Mouse experiment II, s.c.TiterMaxjSP215, 5 days after secondary injection. Grosslyprominent nodule,
white viscous material inside thin capsule in S.c.fat, score 3. Microscopically fairly circumscribed lesion,
essentially composed of large amount of cellular debris within reactive capsule, score 2.5 (HEx 44)
Fig 1F Mouse experiment II, s.c. RIBljno antigen (PBS),5 days after secondary injection. Grossly minimal
amount of white tissue S.c.in the groin, not externally visible, score 0.5. Microscopically moderate diffuse
inflammation, score 1 (HEx 44)
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Fig 1G Mouse experiment II, Lp. Montanide
ISASO/SP21S, 5 days after secondary injection
(omentum). Grossly slight consolidation of omental
edge, score 0.5 (see Table 7). Microscopically in
contrast granulomatous inflammation, mesothelium
prominent or absent, score 3. Also unaffected
omentum present (not shown) (HE x 110)
Experiments III + IV Swelling was observed
at most injection sites of rabbits given
measles or mumps antigen combined with
FA or Specol, especially after secondary
injection (5-20 cm2). When mumps antigen
was combined with Specol, swellings were
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less extensive than when it was combined
with FA. Injection of HlV-peptide conjugates
combined with FA resulted in severe swel-
ling, persistent till the end of the experiment.
Injection of HIV-peptide conjugates com-
bined with Specol resulted in swelling
immediately after injection and slightly
palpable swelling 4 weeks later. Rabbits
injected with Montanide/HIV-peptide
conjugates showed only slight swelling.
Mice
Experiment I Body weights decreased the
first few days after primary injection of FCA/
antigen (five out of six grouPSj5/6) and
Specol/antigen (4/6), and reverted to normal
within one week. Some clinical abnormal-
ities were observed the first few days after
adjuvant/antigen injection. Piloerection
occurred the first 2 days after i.p. primary and
secondary injection with FA/SP215 or FA/
MBP emulsions. After secondary injection,
piloerection occurred in all groups, i.p. or s.c.
given M. pneumoniae combined with an
adjuvant. At s.c. injection sites of FCA/SP2I5
or FCA/MBP nodules (I-4mm) were palp-
able, as in cases when mice were given s.c.
M. pneumoniae with FA or Speco!. The FCA-
induced nodules were present from one week
after injection till the end of the experiment.
Specol nodules had disappeared 4 weeks after
injection. Palpation of injection sites did not
reveal signs of pain. In experiment I, sec-
ondary Lp injection caused the death of the
mice when they were given FIA/SP21S (five








Exp. Antigen" Prime Sect Prim Sec Prim Sec
I SPek1Sa d
I Galacto ++ ++
I M. pneu. ++ + ++
II Rubella ++ + n.d.
II BSA ++ + ++ n.d.
"Antigens described under Table I
bAntigen control (PBS+ antigen injection): no abnormalities
(Maximum swelling at primary (prim) or secondary (sec) injection site







Adjuvant induced side effects in rabbits and mice
out of five). It should be noted that the anti-
gen, and not the adjuvant was responsible for
these deaths. Most probably animals died as a
result of anaphylactic shock as suggested by
time course and observed circulatory dis-
turbances.
Experiment II Piloerection and hunched
posture was observed the first day after
priming i.p. with FCA or TiterMax emul-
sions, and also after secondary immunization
with FIA, TiterMax, Specol or Montanide
emulsions. Mice still showed piloerection
five days after secondary injection with FIA,
TiterMax or Specol. After primary s.c. injec-
tion nodules were palpable in mice injected
with FCA/SP215 (4-8 mm) or TiterMax
(5 mm). Two mice died after secondary i.p.
immunization with FIA/SP215 (2/5). Palpa-
tion of the abdomen of i.p. injected mice or
nodules at the s.c. injection sites did not
reveal signs of pain.
Using the POT procedure, apart from
piloerection we did not observe changes in
behaviour and physiological state. Assuming
that lesions induced by i.p. FCA/antigen
injection are painful} we compared activity at
3 weeks after i.p. injection of FCA/SP215 or
PBS/SP215. There were no differences
between these two groups (data not shown),
indicating that at the time locomotor activity
was minimally disturbed by FCA/SP215
injection.
Behaviour registration system LABORAS
In mice of experiment III, no clinical
abnormalities were observed. The LABORAS
system yielded significant differences in
behavioural patterns between FCA and PBS
injected animals. On the day of injection}
locomotion} climbing, grooming} eating and
drinking were significantly (P < 0.01)
decreased in FCA-injected mice, whereas
immobility was significantly (P < 0.01)
increased in FCA-injected mice as compared
to PBS-injected mice (Fig 2). Two days later
immobility was still significantly (P < 0.01)
increased in FCA-injected mice. Four days
post immunization, no significant differ-




Though changes in clinical and behavioural
parameters in rabbits were not seen, severe
pathological changes did occur in some of
these animals. The pathological changes
observed in experiments I and II are sum-
marized in Table 6. .
Subcutaneous route RIBI and FA induced
the most and more severe lesions than the
other adjuvants. Lesions were often extensive
(up to 100 cm2) and voluminous} combining
proliferative and exudative features. Abscess-
like lesions were observed only in RIBl-trea-
ted rabbits. Specol, TiterMax and Montanide
resulted in lesions at secondary injection
sites mainly (Fig IB). Their presence and
severity depended on the antigen added. Per
adjuvant/antigen combination the overall
severity score of s.c. lesions (Fig 3) was cal-
culated by taking the sum of the mean
primary and secondary lesion score} after
applying a multiplication factor of 1.5 to the
primary lesion score. This factor was applied
to take into account possible reduction over
time and longer duration of primary lesions.
Pathological changes of experiments III and
IV are not summarized in Table 6, since in
these studies four injections, instead of one
at a time} were given. When Specol was
introduced to replace FA in routine poly-
clonal antibody production, combination
with measles and mumps antigen resulted in
unexpectedly severe lesions. In the next ser-
ies Specol and FA were compared} and both
antigens induced extensive (with measles
antigen: more than 200 and more than
300 cm2 respectively and with mumps anti-
gen almost 100 and more than 200 cm2
respectively) haemorrhagic lesions [experi-
ment'III) (Fig lA). Measles antigen without
adjuvant (n = 5) did not induce gross lesions
(data not shown), whereas mumps antigen
(n = 1) induced an abscess-like lesion (60 cm2
totally). Injection of 4 x 0.25 ml FA without
antigen (n = 1) induced extensive necrotizing
granulomas. The same amount of Specol
without antigen (n = 1) resulted in (extensive:
100 cm2) primarily exudative lesions,
whereas after a single dose of 0.1 ml (n = 1)










































































Fig 2 Results of LABORAS behaviour registration system (mice expo III). Behavioural patterns of FCA and PBS
injected (0.2ml i.p.) mice are shown. Relative mean time (±SD) spent on behaviour per day during 4 h
measuring period. *p < 0.01
minimal reaction was found (data not
shown). In experiment IV, Specol and Mon-
tanide combined with HIV-pept/tt at rela-
tively low doses (4 x 0.1 ml) were shown to
induce exudative lesions, which at the most
recently injected sites were more severe than
those induced by FIA/HIV-pept/tt.
Intramuscular route Intramuscular lesions
generally consisted of granulomas spreading
parallel to muscle fibres, and showed less
variation in size and character than s.c.
lesions. Maximum cross diameter was 4 cm
and in general length was 2 to 4 times the
cross diameter. RIBIand FA induced the most
and more severe lesions than the other adju-
vants, which resulted in lesions mainly at
secondary injection sites. The presence and
severity of lesions depended on the antigen
used. Necrosis in i.m. granulomas was com-
monest after RIBI injections. Necrosis of pre-
existent tissue was restricted to four RIBI
cases and one exceptionally severe Specol
(BSA)case. The overall severity score of Lm.
lesions is given in Fig 3; the same calculation
was applied as described for s.c. lesions.
Mice
Subcutaneous route Gross lesions found at
primary injection sites varied slightly within
groups, whereas lesions at secondary injec-
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Table 6 Pathological findings at injection sites of rabbits subcutaneously or intramuscularly injected with
different adjuvant/antigen combinations
Subcutaneous injection' Intramuscular injection
Adjuvant" Antigenb Primary Secondary Primary Secondary
FA SPek1Sa 4d 6 2 S
Galacto 6 4 2 0.5
M. pneu. 6 6 S 0
Rubella 4 5 6 3.5
BSA 5 6 6 5
Specol SPek15a 0 3 0 6
Galacto 0 0 0.5 0.5
M. pneu. 2 6 2 4.5
Rubella 0 0 0 0
BSA 4 6 4 6
RIBI SPek15a 7 4 5 3
Galacto 7 7 6 6
M. pneu. 5 8 5 6
TiterMax SPek15a 1 5 2 5
Galacto 1 2 0 2
M. pneu. 3 6 0 3
Montanide Rubella 0 0 0 1
BSA 2 4 2.5 4.5
"Antigen controls (PBS+ antigen): all primary injection sites negative; secondary injection sites: Galacto (i.m.), M. pneu.
(i.m.) =severity score 1; Galacto (s.c.)=severity score 2
bSPek15a=synthetic peptide; M. pneu. =Mycoplasma pneumoniae; Galacto =galactocerebroside; BSA= bovine serum
albumin
'Comparison between routes is not possible
dMean of severity score at injection site of two rabbits; score asdescribed in Table 3 in 'Animals. materials and methods' section
tion sites were almost identical within
groups. At most primary injection sites of
FCA, TiterMax and Montanide, white or
yellow nodules [2-10 mm) were observed.
Microscopically, granuloma formation, exu-
dative diffuse inflammation and fibrosis were
present at varying degrees (Figs IC-D). Specol
resulted only in marked lesions at the pri-
mary injection sites when combined with M.
pneumoniae. After secondary injection of
Specol/ M. pneumoniae, and in some animals
after secondary injection of TiterMax/SP2I5
or TiterMax without an antigen, circum-
scribed and/or hyperaemic nodules (up to
lOmm) were found. At most secondary
injection sites of other adjuvant/antigen
combinations, grossly white, shiny tissue
attached to muscles was found. Depending
on the amount of this apparently innocuous
reaction, it was visible externally as a white
s.c. area after moistening the coat, and it
caused bulging of the skin in the groin.
Microscopically, diffuse exudative inflam-
mation usually dominated (Figs IE-F), the
severity of which was mostly uniform within
groups and did not always parallel the gross
findings.
For the mean severity score of lesions per
injection site, the sum of macroscopic and
microscopic scores was applied. To obtain an
overall severity score per injected adjuvant/
antigen combination, the sum of the mean
primary lesion score (multiplied by 1.5) and
the mean secondary lesion score was taken
(as described for s.c. lesions in rabbits). The
.overall severity scores obtained in mice
experiment II are given in Fig 4. The score for
FA in this figure (± 12) is representative for
other antigens when combined with FA. The
score of Specol when combined with M.
pneumoniae was higher (10), and when
combined with SP2I5 (experiment I) or MBP
lower (± 2) than the depicted overall severity
score of ± 5 for Specol/SP2I5. Injection of FA
and RIBI in combination with antigen resul-
ted in lesions comparable to those observed
after injection of FA and RIBI without anti-
gen. Specol and Montanide ISA50 without
400 Leenaars et al.
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Fig 3 Overall pathological severity score of lesions after s.c. or i.m. injection of different adjuvant/antigen
mixtures in rabbits (n = 2). For the overall severity score of lesions per adjuvant/antigen combination per route
of injection, primary and secondary lesion scores were summed after applying a multiplication factor of 1.5 for
the former score (see 'Pathological changes' in 'Results' section). Antigen controls (PBS+ antigen) are described
under Table 6
(s.c.) Freund's Specol RIBI TilerMax Montanide ISA50
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overall severity score
Fig 4 Overall pathological severity score of lesions after s.c. injection of adjuvant/SP215 mixtures in mice
(n=2-4). The overall severity score was calculated as described under Fig 3
antigen induced slightly milder lesions than
those found after s.c. inoculation of the same
adjuvants combined with antigen. TiterMax
without antigen caused milder lesions than
TiterMax with antigen. All antigen controls
(antigen + PBS) were grossly negative.
Microscopically, M. pneumoniae/PBS and
SP215/PBS (mice experiment II) injection
resulted in minimal or slight diffuse inflam-
mation at secondary injection sites.
Intraperitoneal route Injection of FA and
TiterMax resulted most consistently in
severe pathological abnormalities. Severity of
lesions caused by Specol depended on the
antigen used. Pathological changes in i.p.
treated mice are summarized in Table 7.
Findings were homogeneous within groups.
Adhesions, often extensive, were seen
between small and large intestines, spleen
and abdominal wall or in the hypogastrium,
with shortening of the ligamentum latum.
The pattern of adhesions was strikingly
comparable within groups. Other signs of
peritoneal irritation were milky effusions
and dilatation of the small intestine. In less
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Table 7 Pathological findings in mice intraperitoneally injected with different adjuvant/antigen combinations
Macroscopy< Macroscopl Microscopy·
Intestinal Omentum Overall Severity Total
Adjuvant" Antigenb Effusions Adhesions dilatation Plaques retrahens score peritonitis scored
FA MBP 0 2 0 2 2 4 4.3 4
M. pneu. 0 0 0 2 1.5 2 4 2
SPill 2 2 0 0 2 4 3 4
-(PBS) 1 0 0.5 0.5 1 3 3 3
Specol SPI 0 0 0 1 0 1 2 1
MBP 0.5 0 0 0.5 0 1 3 1
M. pneu. 0 0 0 1 1.5 2 3 2
SPII 0 2 2 0 2 4 4.5 4
-(PBS) 0 1 2 0 1 4 n.d. 4
RIBI SPII 0 0 0 0.5 0 0 1.7 1
-(PBS) 0 0 0 0 0 0 1.8 1
TiterMax 5PII 2 1 1 0 2 4 2.8 4
-(PBS) 2 1 0.5 1 1 4 n.d. 4
Montanide SPII 0 0 0 1 0.5 1 3.3 2
15A50 -(PBS) 0 0 0 0.5 0.5 1 1.7 1
FCA -(PBS) 0 2 0 1 0 4 n.d. 4
"Antigen controls (PBS+ antigen): grossly and microscopically negative . . .
bSPI= synthetic peptide (mice experiment I); MBP= myelin baSICprotein (autoantlgen); M. pneu. = Mycoplasma pneumonlae,
SPII= synthetic peptide (mice experiment II); - = PBS,no antigen
<Mean macroscopic severity score (n = 4-5): 0 = absent; 1= moderate; 2 = marked
dO = negative-minimal; 1= slight; 2 = moderate; 3 = marked; 4 = severe
"Mean microscopic severity score (n = 3-5): 0 = negative; 1= minimal; 2 =slight; 3 = moderate; 4= marked; 5= severe
fTwo out of five mice died after secondary immunization
severe cases, white} smooth, shiny thicken-
ing of the peritoneum covering liver, dia-
phragm and spleen (designated plaques) and/
or omentun1 retrahens were observed.
Microscopically, severity of peritonitis was
assessed on the basis of·mesothelial altera-
tion, volume and character of peritoneal
infiltrate} hyperaemia} and fibrosis. When no
omentum could be recognized on account of
severe omentum retrahens, the peritoneum
covering the pancreas was analysed instead.
Marked gross signs of active peritonitis were
judged severe, regardless of microscopical
score. In some groups, gross abnormalities
were minimal or slight, though microscopy
revealed peritonitis of unexpected severity.
When this was the case, the total score was
increased when compared to the macroscopic
overall score. Mice in experiment III
(LABORASexperiment) showed no patho-
logical changes after i.p. injection with
PBS,whereas FCA/PBS injection (i.p.) resul-
ted in marked adhesions and plaques (Table
7).
Antibody responses
Figure 5 shows the mean relative antibody
titres (FA= 100%) of the various adjuvant/
antigen combinations. Injection of FA/anti-
gen resulted in high titred} specific antibody
responses independent of the type of antigen.
RIBIdid not induce acceptable antibody
responses, neither in rabbits nor in mice.
TiterMax was not effective in inducing anti-
body responses in rabbits and mice} except
when i.p. injected in mice. Specol and Mon-
tanide ISASOinduced antibody responses
comparable to those induced by FA in rabbits
and mice. Specoljautoantigen injection in
mice, however, did not result in detectable
antibody responseSj Montanide ISASOand
also RIBIand TiterMax had not been injected
in combination with autoantigen.
Discussion
In this paper}FA and alternative adjuvants
were evaluated on their side effects, with the




Fig 5 Relative antibody
titre in serum of rabbits
and mice after injection of
different adjuvant/antigen
combinations. Antibody
titre in serum of FA/anti-










aim of selecting an adjuvant which combines
minor side effects with high antibody titres
for a broad range of antigen types. Injection of
FA resulted in moderate to severe pathologi-
cal changes (Figs 3 and 4; Tables 6 and n
confirming findings of Broderson et al.
(1989), Toth et al. (1989) and Wiedemann et
al. (19911. Literature data on side effects
induced by alternative adjuvants compared
with FA are scarce and relevant information
is often only obtained from clinical observa-
tions. We consider necropsy essential to
determine the side effects induced by adju-
vant injection (e.g. i.m. lesions cannot prop-
erly be monitored in the living animall. In
some cases, we observed extensive lesions at
necropsy, though swellings or nodules were
not palpable. Lesions in rabbits after RIBI
injection were more severe than those
induced by FA (Fig 3). Johnston et al. (1991),
comparing FA, RIBI and Montanide ISASO,
observed no differences in macroscopical
abnormalities induced by these adjuvants. In
contrast, Oeeb et al. (19921 observed mild
lesions after RIBI injection in rabbits. In our
studies in mice, RIBI induced minimal
pathological changes (Fig 4 and Table 7).
Lipman et al. (1992) observed less extensive
lesions (adhesions and white plaques on
organs) after i.p. injection of RIBI in mice
compared with FA-induced lesions. After
injection of TiterMax in rabbits (Fig 3) we
observed slight lesions, whereas injection of
TiterMax in mice resulted in severe lesions
(Fig 4 and Table 71.Bennett et al. (1992) stu-
died histopathological changes after i.m.
injection of 2 x 40 III TiterMax/TNP-HEA in
mice and found mild lesions. In our study,
Montanide ISASOinjections resulted gen-
erally in less severe lesions when compared
to FA injections, both in rabbits and mice
(Figs 3 and 4; Tables 6 and 7j. Johnston et al.
(1991) injected rabbits with Montanide ISASO
and observed similar lesions as those induced
by FCA. These differences in pathological
changes between this study by Johnston et al.
(1991) and our study may be explained by the
fact that different antigens were used.
Pathological investigation was performed
at the end of each experiment. Consequently,
continuous monitoring of the lesions by
macros copy and microscopy was not pos-
sible. Generally, the monitoring time point
was 2 weeks in rabbits and 5 days in mice
after secondary injection, so that lesions at
primary injection sites were present at least 6
weeks. To discriminate between primary and
secondary injections, they were given at dif-
ferent sites. Primary injection sites were
negative more often that secondary ones.
Apart from healing of the inflammation,
immunopathological phenomena (as a result
of repeated introduction of antigen I are likely
to playa role in secondary lesions. As there
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was only one point of monitoring, rapidly
resolving inflammatory reactions may have
been missed, especially in rabbits (lesions at
least 2 weeks old). A certain lesion, found at
the primary injection site (at least 6 weeks
old), is presumed to have impaired the animal
more than an identical lesion found at the
secondary injection site. To compensate for
this, scores of primary injection sites were
augmented by a factor 1.5before summing up
primary and secondary scores, and reaching
an overall severity score per adjuvant/antigen
combination (Figs3 and 4).
Microscopy was performed because it adds
useful observations to gross data. Lesions at
s.c. injection sites in mice showed some
remarkable differences in macroscopic and
microscopic findings. At the s.c. primary
injection site in mice, grossly observed
impressive nodules occasionally appeared to
consist merely of one or several large 'oil
spaces' surrounded by slight or moderate
(fibrolgranulomatous proliferation. On the
other hand, macroscopically identically
scored lesions were found to display marked
diffuse and granulomatous inflammation and
marked fibrosis around variably sized 'oil
spaces'. Microscopical examination of s.c.
secondary injection sites in mice revealed
grossly unexpected severe inflammation in
some groups. It is not known why these
microscopically marked exudative lesions
are hardly seen macroscopically. Haemor-
rhage was absent in lesions in mice but was
present in lesions in rabbits that showed
marked hyperaemia in exudative lesions
despite exsanguination. When macroscopical
examination of s.c. and i.m. injection sites
does not reveal pathological changes, addi-
tional information from microscopy depends
on successful sampling. The i.p. route can
always be monitore~ microscopically and
mild or resolving peritonitis (missed grossly)
can be assessed in a more sensitive way. As in
rabbits macroscopical severity correlated
well with microscopical severity, microscopy
was only used to verify gross findings. The
same holds true for the i.p. route in mice. In
s.c. treated mice, macro- and microscopical
findings were taken together, because these
findings did not correlate well. Apart from
the adjuvant, other factors may determine
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the severity of lesions, e.g. antigen type and
injection route. The lesions seen after injec-
tion of M. pneumoniae combined with all
tested adjuvants were relatively severe in
rabbits. Hardly any lesion was observed when
it was injected without an adjuvant. In
combination with measles or mumps
antigen, Specol induced extensive lesions
(less extensive than FAl in rabbits, whereas
in combination with other antigens (e.g.
synthetic peptide, glycolipid) it induced
minimal to mild lesions. This may be
explained by either the volume injected
(4x 0.25ml) or the particulate character of
the antigens.
Severity of lesions cannot simply be
compared between injection routes. In our
opinion the i.p. injection route should be
rejected, owing to the extensive surface of
the peritoneum, its high susceptibility to
physicochemical damage and its intimate
contact with various vital organs. Especially
the acute phase of peritonitis is believed to be
painful. In abdominal tissue of mice, we
observed acute exudative inflammation 2 to
96 h after i.p. FCA/TNP-KLH injection
(0.2ml) (data not shown). Jansen van 't Land
and Hendriksen (19951 showed decreased
locomotor activity on the first day after i.p.
injection of 0.2ml FCA. In our LABORAS
experiment, locomotion, climbing, groom-
ing, eating and drinking were significantly
reduced after i.p. injection of FCAjPBS (Fig
2). In addition, secondary injection via the
i.p. route caused some deaths, probably on
account of systemic reactions. In rabbits the
pathological findings do not clearly point at a
preferential route. The i.m. route is more
prone to injection error (i.e. wrong localiza-
tion of adjuvant/antigen mixture) and more
painful than the s.c. one. Moreover, Lm.
lesions are more difficult to monitor clini-
cally. The s.c. loose areolar tissue will permit
spread of inoculum and inflammation more
easily than the rigid muscle compartment,
indeed resulting in larger s.c. lesions. Intra-
muscular lesions probably exert more pres-
sure on the surrounding tissue. Hence,
considering the s.c. and i.m. route, pain
experienced by the animal is not only a
function of lesion size and character.
Although s.c. lesions were sometimes very
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extensive, we find reason to prefer the s.c.
route to the i.m. route.
An effective adjuvant (Fig 5) that induces
minimal pain in the animals is preferred for
immunization. In rabbits, no clinical or
behavioural changes indicating pain and dis-
tress were observed. Mice revealed signs of
acute pain and distress (e.g. weight loss,
decrease in activity and piloerection) during
the first few days after injection. Although
signs of prolonged severe pain and distress
were absent, marked to severe pathological
changes did occur after injection of several of
the adjuvant/antigen mixtures (Figs 3 and 4;
Tables 6 and 7). It is not possible to give an
estimation of pain associated with the
observed pathological changes, because we
did not observe indications of prolonged pain
and distress. In mice, only acute distress was
found. The available methods may be inade-
quate to monitor prolonged pain and distress,
especially in the rabbit, because this species
does not readily exhibit pain signs (Wallace et
a1. 1990, Griffiths 1991). Mice showed signs
of acute pain; if they experienced prolonged
pain this was not revealed by clinical and
behavioural changes, indicating that they are
able to cope with the induced pathological
changes or that these changes are not or less
painful than is presumed. Devices like
LABORAS (Van de Weerd 1996, Bulthuis et a1.
1997) enable the recording of subtle changes
in the behavioural pattern of mice, offering
the possibility to monitor pain and distress.
We injected the animals in accordance
with the Dutch guidelines for the immuni-
zation of laboratory animals, e.g. FCA in
primary and FlA in secondary injection. This
may be the reason why minimal signs of pain
and distress were found. Johnston et a1.
(1991) did not observe indications for pain in
rabbits, although marked pathological chan-
ges were found. Amyx (1987) suggested that
most undesirable effects of FCA can be
eliminated by careful control of injection
quantity and site selection. The pathological
changes induced by FCA are thought to be
(potentiallyl very painful, in analogy to
humans. Therefore, reports on accidental and
intentional human injections can provide
information on pain induced by FCA. Chapel
and August (1976) reported severe pain after
Leenaars et al.
accidental injections in humans. However,
all persons who suffered severe pain were
positive to the tuberculin test prior to the
accidental injection, indicating that the
reaction was a result of repeated exposure to
mycobacteria (Stills & Bailey 1991). Wanstrup
and Christensen (19651 injected mice weekly
with FCA and observed decreased activity,
dullness of fur and loss of hair.
In conclusion, we did not observe clinical
and behavioural changes indicative for severe
prolonged pain and distress (only acute dis-
tress in mice was observed), although some
adjuvants were associated with severe
pathological changes in this study. Patholo-
gical changes are considered an essential
parameter to study side effects of adjuvants.
The s.c. route is superior to the i.m. route
(rabbitsl or i.p. route (mice). Montanide
ISA50 and Specol appear to induce acceptable
antibody responses and less pathological
changes than FA, and are, therefore, effective
alternatives to FA in many situations.
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